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Two cases of community-acquired septicemia caused
by serotype-O1 Yersinia pseudotuberculosis were diag-
nosed in middle-aged, HIV-positive, immunodeficient
patients during an 8-month period. Bacterial isolates were
genetically indistinguishable, but no epidemiologic link
between the 2 patients was established. HIV-related
immunosuppression should be regarded as a risk factor for
Y. pseudotuberculosis septicemia.
Y
ersinia pseudotuberculosis is a rare cause of disease in
humans. Animals, food, and the abiotic environment
are Y. pseudotuberculosis reservoirs from which epizootic
and human infection may arise (1). A geographic gradient
of Y. pseudotuberculosis isolation rates has been reported
in Europe (1,2), with a 0.05% recovery rate from stools of
patients with acute enteritis in Italy (3). The organism can
also cause mesenteric lymphadenitis, which mimics
appendicitis, or infection at other body sites that occasion-
ally leads to postinfectious sequelae such as reactive arthri-
tis and erythema nodosum (1). About 60 cases of Y.
pseudotuberculosis septicemia have been reported thus far,
mainly in patients with underlying conditions such as
hepatic cirrhosis, malignancy, diabetes, aplastic anemia,
thalassemia, and iron overload (1,4,5). We recently report-
ed the first case of Y. pseudotuberculosis septicemia in a
severely immunocompromised, HIV-positive patient (6).
Here, a second case of Y. pseudotuberculosis septicemia in
an HIV-infected outpatient attending the same hospital is
described. The unique molecular type of both Y. pseudotu-
berculosis isolates and the atypical clinical course of infec-
tion will be comparatively discussed.
The Study
The first case has recently been reported (6) and is
briefly reviewed here. Patient 1 was a 42-year-old woman
with HIV infection since 1987 (Centers for Disease Control
and Prevention [CDC] Classification C3). In June 2003, she
was admitted to the National Institute for Infectious
Diseases, Rome, from prison because of high fever and
confusion. Physical examination showed a temperature of
39.5°C, abnormal mental status, and oral candidiasis, but
no gastrointestinal symptoms. Her history included lack of
response to highly active antiretroviral therapy (HAART),
and she exhibited HIV viremia of 413,624 copies/mL, a
low CD4+ cell count (5/mm3), and leukopenia (3.0 ×
103/mm3). Laboratory values were altered for aminotrans-
ferases (aspartate aminotransferase, 273 U/L; alanine
aminotransferase, 77 U/L), hemoglobin (7.0 g/dL), erythro-
cyte sedimentation rate (136 mm in the first hour), and
platelet count (34 × 103/mm3). Multiple blood cultures
yielded growth of Y. pseudotuberculosis. Stool cultures and
test results for antibodies against Y. pseudotuberculosis
were negative. Intravenous ceftriaxone therapy was started
at admission, with total remission of symptoms in 4 days.
No recurrence of Y. pseudotuberculosis infection was
observed during a 1-year follow-up period.
Patient 2 was a 54-year-old man who was admitted to
the same hospital in February 2004 because of sudden
fever and confusion. He tested HIV-positive in 1993 (CDC
Classification B3), and his CD4+ cell count nadir was 121
cells/mm3. His recent antiretroviral therapy was a combi-
nation of stavudine, lamivudine, and nelfinavir. HCV-
related liver cirrhosis was diagnosed 3 years before this
admission. His condition was routinely followed up in the
outpatient unit, and he had been hospitalized 1 month ear-
lier for culture-negative pneumonia in the left lower lobe.
On admission, the patient had a high fever (41°C), chills,
and abnormal mental status with somnolence. Results of a
chest radiograph, nuclear magnetic resonance imaging of
the brain, and echocardiogram were normal. HIV viremia
level was <50 copies/mL and CD4+ cell count was 204
cells/mm3. Laboratory values were notable for leukocyto-
sis (leukocytes, 14 × 103/mm3), anemia (hemoglobin, 10
g/dL), and thrombocytopenia (platelets, 69 × 103/mm3).
Levels of C reactive protein, aminotransferases, blood glu-
cose, creatinine, urea nitrogen, and electrolytes were with-
in the normal range. Liver cirrhosis was classified as
Child-Pugh group B, score 7. Urine was negative for opi-
oids and cocaine metabolites. On second day postadmis-
sion, multiple blood cultures became positive for Y.
pseudotuberculosis, while stool cultures were negative.
Intravenous ceftriaxone therapy was begun at admission,
with total remission of symptoms within 3 days. He was
discharged on day 10 and continued intravenous ceftriax-
one therapy for 4 weeks (2 g daily) as an outpatient. At the
final clinical observation, 6 months later, the patient was
free of clinical symptoms and had no recurrence of Y.
pseudotuberculosis infection.
Blood culture isolates from both patients were identi-
fied with >99% confidence as Y. pseudotuberculosis by
using both the API20E-Rapid test (bioMérieux, Marcy
l’Etoile, France) and the BD Phoenix system (Becton
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ed spectrum of antimicrobial susceptibility (sensitive to β-
lactams, monobactams, aminoglycosides, quinolones, and
sulfonamides). O-serotyping with commercial antisera
(Denka Seiken, Tokyo, Japan) identified both organisms as
Y.  pseudotuberculosis serotype O1, consistent with the
high frequency of this serotype among strains isolated
from patients with septicemia in Europe (2). 
The 16S ribosomal DNA(rDNA) sequences were iden-
tical in the 2 isolates and optimally matched (>99% identi-
ty) the 16S rDNA of the Y. pseudotuberculosis type strain
ATCC 29833 (GenBank accession no. AF366375). To dif-
ferentiate the strains at the genome level, amplified frag-
ment length polymorphism and arbitrarily primed
polymerase chain reaction (PCR) were performed (7–9).
While these methods are highly discriminatory and detect
DNA polymorphisms to the strain level, no differences
between the 2 clinical isolates were observed (Figure, pan-
els A and B).
To gain insight into the pathogenic potential of the 2
isolates, we assessed the presence of pYV (70-kb virulence
plasmid), high pathogenicity island (HPI), and Y. pseudo-
tuberculosis–derived mitogen (YPM) genetic markers by
PCR (2,6). Both isolates harbored a characteristic reper-
toire of virulence determinants. Correctly sized PCR prod-
ucts were obtained for inv (chromosome-borne), irp1, irp2,
IS100 (HPI-borne), lcrF, and yadA (plasmidborne) genes
(Figure, panel C). The identity of PCR products was con-
firmed by direct DNA sequencing. Interestingly, both iso-
lates were negative for the ypmA (chromosome-borne)
gene, consistent with the genetic instability of this marker
which is typically absent in strains from Western countries
(2,10). Reducing PCR stringency for ypmA yielded a 237-
bp amplicon, which resulted from mispriming of oligonu-
cleotides on the Y. pseudotuberculosis hmp flavohemo-
protein gene (data not shown). 
Molecular typing and virulence gene probing indicate
that both cases resulted from indistinguishable Y. pseudo-
tuberculosis strains, which raises the suspicion of a com-
mon source of infection. However, no other cases of Y.
pseudotuberculosis infection were diagnosed in our insti-
tute or reported to the National Center for
Enteropathogenic Bacteria, Istituto Superiore di Sanità,
Rome, from January 2003 to June 2004 (I. Luzzi, pers.
comm.). In September 2004, patients were interviewed
about their lifestyle, illness, food and fluid consumption,
or animal exposure in the 2 weeks preceding hospitaliza-
tion. Nosocomial infection and direct contact between
patients were ruled out, which suggested that infection had
been independently acquired in the community. Both
patients denied any contact with wild or domestic animals.
Patient 1 had not been released from detention in the 6
months preceding hospitalization and regularly consumed
collective meals in prison. However, prison infirmary
records did not show an increased frequency of abdominal
symptoms or fever among ≈500 inmates from May to July
2003. Patient 2 was a heavy smoker who had been abusing
alcohol and illicit drugs until 2001. He lived alone and had
a seafood meal 4 days before admission. Thus, although
infection may have been acquired from contaminated food
or fluid, questions regarding the actual source of bacteria
and the extent of exposure remain unanswered.
Conclusions
AIDS is a known risk factor for Y. enterocolitica infec-
tion (11), but no link between HIV and Y. pseudotubercu-
losis infection has yet been proposed. Yersiniae have an
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Figure. Genetic fingerprinting and detection of virulence genes of
Yersinia pseudotuberculosis isolates. A) Fluorescent amplified
fragment length polymorphism (AFLP) analysis of Y. pseudotuber-
culosis DNA (black electropherogram; 1 and 2 refer to patient
number). Reactions were performed as indicated in the AFLP
Microbial Fingerprinting kit (Applied Biosystems, Foster City, CA,
USA). Reference DNA from Escherichia coli W3110 (Applied
Biosystems) was used as internal control (gray electropherogram).
Separation and detection of the AFLP fragments were performed
with the Applied Biosystems model 3100 capillary electrophoresis
system equipped with a 36-cm capillary loaded with the POP-4
polymer. Size determinations of the labeled DNA fragments were
performed automatically with the Genescan Analysis 3.0 software
(Applied Biosystems). B) Arbitrarily primed polymerase chain reac-
tion (AP-PCR) analysis with a set of 6 oligonucleotides: AP5 (5´-
TCCCGCTGCG-3´), AP12 (5´-CGGCCCCTGC-3´), AP42 (5´-
AACGCGCAAC-3´), AP44 (5´-AGCCAGTTTC-3´), AP46 (5´-GAG-
GACAAAG-3´), and AP270 (5´-TGCGCGCGGG-3´) (8,9).
Amplification patterns of DNA from the 2 clinical isolates are
shown: lane 1, patient 1; lane 2, patient 2. M, molecular weight
marker. The numbers on the left indicate the length (in base pairs)
of the reference ladder. Primers are indicated on top. C) Detection
of Y. pseudotuberculosis virulence genes. Primers and PCR con-
ditions have been described elsewhere (2,6). Lane 1, patient 1;
lane 2, patient 2. Lane M, molecular weight marker. The numbers
on the left indicate the length (in base pairs) of the reference lad-
der. Target genes are indicated on top.impaired iron metabolism, and for this reason, they rarely
cause sepsis in patients without iron overload, which is
often secondary to alcoholism, asplenia, hemochromatosis,
thalassemia major, or tobacco smoking (1). In our 2
patients, no clinical evidence indicated iron overload, and
a diagnosis of hemochromatosis was excluded. The most
important risk factor was HIV-related severe immunodefi-
ciency. Patient 1 was severely immunocompromised
despite HAART, while patient 2 responded poorly to
HAART and had hepatitis C–related liver cirrhosis.
Although the clinical management of Y. pseudotubercu-
losis septicemia is often difficult and mortality rates are
high (≈75%), despite antimicrobial drug therapy (1), both
our patients responded unexpectedly well to ceftriaxone
therapy and promptly recovered. During infection, Y.
pseudotuberculosis directly manipulates lymphocyte sig-
naling and activation by expressing different virulence fac-
tors (12). The pYV plasmid-encoded Yop proteins have
been implicated in lymphocyte suppression through down-
regulation of co-stimulatory molecules (13) and impair-
ment of nitric oxide, tumor necrosis factor (TNF)-α, and
proinflammatory cytokine production (14). Conversely,
YPM superantigen(s) contribute to systemic illness by
activating a large proportion of T cells (essentially CD4+)
and inducing proinflammatory cytokines such as TNF-α,
TNF-β, γ-interferon, and interleukins 1 and 6, as in toxic
shock syndrome (15). Our experimental data show that the
2 clinical strains were positive for all the virulence genes
tested, except for ypmA. Even considering the different
degree of immunodeficiency between the 2 patients, we
speculate that impairment of immune response secondary
to HIV infection may have increased the susceptibility to
Y. pseudotuberculosis infection while mitigating the septic
shock sequelae. Accordingly, the inflammatory response
consequent to T-cell activation may have been attenuated
by the deficiency of CD4+ cells in both patients, concomi-
tant with the lack of YPM expression by both Y. pseudotu-
berculosis isolates. In conclusion, these 2 cases indicate
that Y. pseudotuberculosis is an emerging pathogen in HIV
patients and remind us that septicemia in these patients can
exist without prodromic symptoms. They also alert us to
the local circulation of a pathogenic Y. pseudotuberculosis
strain whose natural reservoir remains so far unknown.
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